Navigation Links
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

- Conference Call Scheduled for 9:00 AM ET Today -

SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial designed to assess the safety and efficacy of the investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with metastatic androgen-independent prostate cancer. While Dendreon remains blinded to the data, the independent data monitoring committee (IDMC) reported to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC observed no safety concerns and recommended that the study continue to its final analysis.

"The treatment effect we have observed in this interim analysis is consistent with that observed in the integrated analysis of our previous Phase 3 trials in this patient population when analyzed at a similar 24-month follow-up time," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Given the delayed treatment effect we have seen in previous studies, we are pleased to see evidence suggesting a prolongation of survival in the PROVENGE arm at the time of the interim analysis, as well as a favorable safety profile."

At the final analysis, which is anticipated in the middle of 2009, if the study demonstrates approximately a 22 percent reduction in the risk of death, based on 304 events, the company would expect the study to meet its primary endpoint of overall survival.

"We look forward to the final results next year and the opportunity to make PROVENGE available to the many men with advanced prostate cancer who currently have few appealing treatment options," said Dr. Gold.

The IMPACT trial is a randomized,
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
2. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
6. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
11. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Reportlinker.com announces that a new market ... Respiratory Devices - Global ... to 2016 http://www.reportlinker.com/p0240243/Respiratory-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Global Pipeline Analysis, Opportunity Assessment and Market ...
... 14 AAIPharma Services Corp., a leading provider of ... announced today that it has appointed Patrick D. Walsh ... equity firm focused exclusively on health care that acquired ... company in 2009, was instrumental in recruiting Mr. Walsh ...
Cached Medicine Technology:Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 2AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 3
(Date:7/12/2014)... 2014 A recent article released by Seattle's ... of suggestions for those seeking cosmetic surgical procedures in ... approaching and the heat begins to enliven the rainy Pacific ... clothing, realizing that they didn’t work out as much during ... cause a sudden surge of people eager to look their ...
(Date:7/12/2014)... FL (PRWEB) July 12, 2014 Maxim ... high-quality peptides that are used solely in scientific experiments, ... two successful years in business, Maxim Peptide, which was ... just launched a new and updated website that now ... blog section has been updated with fascinating articles about ...
(Date:7/11/2014)... Va. (PRWEB) July 11, 2014 The ... at America’s 55 poison centers are commending Senator Bill ... Poison Prevention Act of 2014 on July 10, 2014. ... U.S. Consumer Products Safety Commission (CPSC) to enact rules ... to consumers. , Senate co-sponsors of the ...
(Date:7/11/2014)... Reducing the number of deer in an area can ... tick-borne infections among people, new research indicates. "Our ... reduce human interactions with deer, infected nymphal ticks and ... White-tailed deer are the primary host for adult ... The study included nearly all the permanent residents of ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has been ... Food & Drug Administration’s (FDA) Obstetrics and ... explore ways to mitigate the cancer risks associated ... invasive gynecological surgeries. According to a report published ...
Breaking Medicine News(10 mins):Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... Day of Fall, September 22, Focuses on Preventing ... Today Congress issued,another call to action urging government, ... prevent the increasing number of falls,among people 65 ... (D-MD),and Mike Enzi (R-WY), as well as Representatives ...
... the 2006 Medicare Current Beneficiary Survey, WASHINGTON, ... option for low and moderate income seniors and ... data from the Medicare,Current Beneficiary Survey (MCBS)., ... and those,living in rural areas, rely on Medigap ...
... Olympic Games Champion Nikki Stone and Chronic Pain ... 22 The American Society of Pain,Educators (ASPE) ... Is Your Persistent Chronic Pain Weighing You Down? ... of proper,weight control in managing chronic pain., ...
... therapy delivered in only a week , , MONDAY, Sept. ... radiosurgery may be a viable treatment for recurring pancreatic ... Center, using their precise CyberKnife to perform radiosurgery, had ... the date of treatment. The range of survival was ...
... babies. , Now, it appears how infants respond to stress ... certain gene, according to a new study from the University of ... say they have also found that good parenting as early ... counter the effect the gene has in babies who initially do ...
... Enables SPECT Procedures ... New ASNC Technology Standards, POWAY, Calif., Sept. 22 ... imaging systems and,services to physicians, offices, hospitals and other medical ... Drug,Administration (FDA) 510(k) clearance for its new nSPEED(R) reconstruction,software -- ...
Cached Medicine News:Health News:Home Safety Council(R) Applauds Creation of Falls Prevention Awareness Day 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 3Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 4Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 5Health News:Radiosurgery Proves Viable for Some Pancreatic Cancers 2Health News:UNC study: Parenting can override effect of genes in how babies respond to stress 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 3
... for vascular treatments, Smart VS is the most ... fast amortisation of the investment made. Like all ... with a polarised light viewing system for ensuing ... as well as the operators maximum comfort. I ...
... is an exceptional condensate of ... dimensions for ensuring a rational ... constantly evolving professional market. PhotoLight ... in different studios who require ...
... 2000 system is a pulsed DYE laser ... specific pathologies like Port Wine Stains (PWS), ... pathologies of the trunk and the face. ... all these pathologies, the DYE laser naturally ...
... Plus is a CO2 laser system ... W. Its functions in continuous and ... requiring extreme laser intervention delicacy. Excellent ... studios, it comes with a large ...
Medicine Products: